Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Current and Emerging Biological and Oral/Topical Small-Molecule Treatments for Psoriasis
share announcement

Current and Emerging Biological and Oral/Topical Small-Molecule Treatments for Psoriasis

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 5698

Special Issue Editor

Prof. Dr. Tiago Torres

E-Mail Website
Guest Editor
1. Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal
2. Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal
Interests: psoriasis; atopic dermatitis; immunemediated diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Psoriasis is a chronic, systemic, immune-mediated disease associated with several comorbidities. Although its pathogenesis is complex and not yet fully understood, the interleukin (IL)-23/IL-17 axis is currently thought to be its main pathogenic pathway. The knowledge acquired over the last decade regarding psoriasis’s pathogenesis has led to the development of new targeted therapeutic options including biologic agents and small molecules (both oral and topical) that enable clinicians to better manage psoriasis patients. Main targets include cytokines related to the IL-23/IL-17 axis and their intracellular signalling pathway (JAK-STAT, PDE4 and others); however, many other agents (topical, oral and parenteral drugs) with different targets are in the pipeline. This Special Issue aims to review recent and future therapy developments for the treatment of psoriasis.

Prof. Dr. Tiago Torres
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • psoriasis
  • pustular psoriasis
  • biologic therapies
  • small molecules
  • psoriasis pathogenesis
  • TNF
  • IL-23
  • IL-17
  • TYK2
  • IL-36
  • inflammation
  • pipeline

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 12785 KiB  
Article
A Promising Approach to Treat Psoriasis: Inhibiting Cytochrome P450 3A4 Metabolism to Enhance Desoximetasone Therapy
by Jiun-Wen Guo, Yu-Pin Cheng, Cherng-Jyr Lim, Chih-Yi Liu and Shiou-Hwa Jee
Pharmaceutics 2023, 15(8), 2016; https://doi.org/10.3390/pharmaceutics15082016 - 25 Jul 2023
Viewed by 960
Abstract
(1) Background: Human keratinocytes and murine skin express various cytochrome P450 enzymes. These include cytochrome P450 3A4, which may participate in the metabolism of cytochrome P450 3A4 substrate drugs. Desoximetasone, a topical corticosteroid and cytochrome P450 3A4 substrate, is used to treat skin [...] Read more.
(1) Background: Human keratinocytes and murine skin express various cytochrome P450 enzymes. These include cytochrome P450 3A4, which may participate in the metabolism of cytochrome P450 3A4 substrate drugs. Desoximetasone, a topical corticosteroid and cytochrome P450 3A4 substrate, is used to treat skin conditions such as skin allergies, atopic dermatitis, and psoriasis. In this study, we aimed to investigate the anti-psoriatic effect of a low dose of desoximetasone by inhibiting cytochrome P450 3A4 metabolism in the epidermis. (2) Methods: Psoriasis-like skin was induced in BALB/c mice via the topical administration of imiquimod. The mice were then topically treated with 0.01–0.05% desoximetasone loaded into a cytochrome P450 3A4 enzyme inhibitor excipient base emollient microemulsion, 0.25% commercial desoximetasone ointment, or 0.5 mg/gm clobetasol ointment. (3) Results: The topical application of 0.05% desoximetasone loaded into a cytochrome P450 3A4 enzyme inhibitor excipient base emollient formulation restored the imiquimod-induced skin barrier disruption and resulted in fewer severe clinical and pathological features compared with the treatments with 0.25% commercial desoximetasone ointment and 0.5 mg/gm clobetasol ointment. (4) Conclusions: The cytochrome P450 3A4 enzyme inhibitor excipient base emollient formulation improved and prolonged the therapeutic effect of cytochrome P450 3A4 substrate drugs and may be a promising approach for psoriasis treatment. Full article
(This article belongs to the Special Issue Current and Emerging Biological and Oral/Topical Small-Molecule Treatments for Psoriasis)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

36 pages, 1088 KiB  
Review
New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis
by Elena Carmona-Rocha, Lluís Rusiñol and Lluís Puig
Pharmaceutics 2024, 16(2), 239; https://doi.org/10.3390/pharmaceutics16020239 - 6 Feb 2024
Cited by 1 | Viewed by 2187
Abstract
The introduction of biologic therapies has led to dramatic improvements in the management of moderate-to-severe psoriasis. Even though the efficacy and safety of the newer biologic agents are difficult to match, oral administration is considered an important advantage by many patients. Current research [...] Read more.
The introduction of biologic therapies has led to dramatic improvements in the management of moderate-to-severe psoriasis. Even though the efficacy and safety of the newer biologic agents are difficult to match, oral administration is considered an important advantage by many patients. Current research is focused on the development of oral therapies with improved efficacy and safety compared with available alternatives, as exemplified by deucravacitinib, the first oral allosteric Tyk2 inhibitor approved for the treatment of moderate to severe psoriasis in adults. Recent advances in our knowledge of psoriasis pathogenesis have also led to the development of targeted topical molecules, mostly focused on intracellular signaling pathways such as AhR, PDE-4, and Jak-STAT. Tapinarof (an AhR modulator) and roflumilast (a PDE-4 inhibitor) have exhibited favorable efficacy and safety outcomes and have been approved by the FDA for the topical treatment of plaque psoriasis. This revision focuses on the most recent oral and topical therapies available for psoriasis, especially those that are currently under evaluation and development for the treatment of psoriasis. Full article
(This article belongs to the Special Issue Current and Emerging Biological and Oral/Topical Small-Molecule Treatments for Psoriasis)
►▼ Show Figures

Figure 1

15 pages, 301 KiB  
Review
Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents
by Anastasia Drakos, Tiago Torres and Ronald Vender
Pharmaceutics 2024, 16(1), 111; https://doi.org/10.3390/pharmaceutics16010111 - 15 Jan 2024
Cited by 1 | Viewed by 2242
Abstract
The introduction of biologic agents for the treatment of psoriasis has revolutionized the current treatment landscape, targeting cytokines in the interleukin (IL)-23/IL-17 pathway and demonstrating strong efficacy and safety profiles in clinical trials. These agents however are costly, are associated with a risk [...] Read more.
The introduction of biologic agents for the treatment of psoriasis has revolutionized the current treatment landscape, targeting cytokines in the interleukin (IL)-23/IL-17 pathway and demonstrating strong efficacy and safety profiles in clinical trials. These agents however are costly, are associated with a risk of immunogenicity, and require administration by intravenous or subcutaneous injection, limiting their use among patients. Oral therapies, specifically small molecule and microbiome therapeutics, have the potential to be more convenient and cost-effective agents for patients and have been a focus of development in recent years, with few targeted oral medications available for the disease. In this manuscript, we review pipeline oral therapies for psoriasis identified through a search of ClinicalTrials.gov (30 June 2022–1 October 2023). Available preclinical and clinical trial data on each therapeutic agent are discussed. Small molecules under development include tumor necrosis factor inhibitors, IL-23 inhibitors, IL-17 inhibitors, phosphodiesterase-4 inhibitors, Janus kinase inhibitors, A3 adenosine receptor agonists, and sphingosine-1-phosphate receptor 1 agonists, several of which are entering phase III trials. Oral microbials have also demonstrated success in early phase studies. As new oral therapies emerge for the treatment of psoriasis, real-world data and comparative trials are needed to better inform their use among patients. Full article
(This article belongs to the Special Issue Current and Emerging Biological and Oral/Topical Small-Molecule Treatments for Psoriasis)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop